GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

GAMMA Investing LLC increased its stake in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) by 134.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,333 shares of the company’s stock after purchasing an additional 4,773 shares during the quarter. GAMMA Investing LLC’s holdings in Silence Therapeutics were worth $48,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Ameriprise Financial Inc. bought a new position in Silence Therapeutics in the 4th quarter valued at $113,000. Jump Financial LLC bought a new position in Silence Therapeutics in the 1st quarter valued at $74,000. Finally, Walleye Capital LLC boosted its holdings in Silence Therapeutics by 274.1% in the first quarter. Walleye Capital LLC now owns 136,150 shares of the company’s stock valued at $384,000 after acquiring an additional 99,753 shares during the last quarter. 98.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on SLN. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Tuesday, September 16th. Wall Street Zen lowered shares of Silence Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 target price on shares of Silence Therapeutics in a research note on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Saturday, September 27th. Five equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $32.60.

Silence Therapeutics Stock Performance

Shares of NASDAQ:SLN opened at $5.00 on Friday. Silence Therapeutics PLC Sponsored ADR has a 12 month low of $1.97 and a 12 month high of $20.48. The company’s fifty day simple moving average is $5.30 and its 200 day simple moving average is $4.81.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.27). Silence Therapeutics had a negative net margin of 294.20% and a negative return on equity of 67.48%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $8.50 million. Sell-side analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.77 EPS for the current year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.